Coya Therapeutics Inc (COYA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.94-4.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Coya Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	660,000
EPS	—	-0.371
Annual ending 2026-12-31
Revenue	—	1.02M
EPS	—	-1.326
Annual ending 2027-12-31
Revenue	—	5.95M
EPS	—	-1.445

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway into 2027	The company has maintained cash runway into 2027, supporting ongoing development.	Intact	Cash reserves fall short of sustaining operations into second half of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net loss per share	A supporting condition in Coya Therapeutics Inc's published investment case. The stated target is EPS loss less negative than -$1.83 per share.	Intact	EPS loss worsens beyond -$1.83 per share in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize or improve revenue trajectory	A primary condition in Coya Therapeutics Inc's published investment case. The stated target is Revenue decline less than -10% YoY or positive growth.	Improving	Revenue decline exceeds -10% YoY in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.00B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$4,961,833	3 / 6
2026-07-25	Unavailable	$4,961,833	3 / 6
2026-07-26	Unavailable	$4,961,833	3 / 6
2026-07-27	Unavailable	$4,961,833	3 / 6
2026-07-28	Unavailable	$4,961,830	3 / 6
2026-07-29	Unavailable	$4,961,833	3 / 6
2026-07-30	Unavailable	$4,961,830	3 / 6
2026-07-31	Unavailable	$4,961,830	3 / 6
2026-08-01	Unavailable	$4,961,833	3 / 6
2026-08-02	Unavailable	$4,961,830	3 / 6
2026-08-03	Unavailable	$4,961,830	3 / 6
2026-08-04	Unavailable	$4,961,833	3 / 6
2026-08-05	Unavailable	$4,961,833	3 / 6
2026-08-06	Unavailable	$4,961,830	3 / 6
2026-08-07	Unavailable	$4,961,833	3 / 6
2026-08-08	Unavailable	$4,961,833	3 / 6
2026-08-09	Unavailable	$4,961,833	3 / 6
2026-08-10	Unavailable	$4,961,833	3 / 6
2026-08-11	Unavailable	$4,961,833	3 / 6
2026-08-12	Unavailable	$4,961,833	3 / 6
2026-08-13	Unavailable	$4,961,833	3 / 6
2026-08-14	Unavailable	$4,961,833	3 / 6
2026-08-15	Unavailable	$4,961,833	3 / 5
2026-08-16	Unavailable	$4,961,833	3 / 5
2026-08-17	Unavailable	$4,961,833	3 / 5
2026-08-18	Unavailable	$4,961,833	3 / 6
2026-08-19	Unavailable	$4,961,833	3 / 6
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	3 / 4
2026-09-12	Unavailable	Unavailable	3 / 4
2026-09-13	Unavailable	Unavailable	3 / 4
2026-09-14	Unavailable	Unavailable	3 / 4
2026-09-15	Unavailable	Unavailable	3 / 4
2026-09-16	Unavailable	Unavailable	3 / 4
2026-09-17	Unavailable	Unavailable	3 / 4
2026-09-18	Unavailable	Unavailable	3 / 4
2026-09-19	Unavailable	Unavailable	3 / 4
2026-09-20	Unavailable	Unavailable	3 / 4
2026-09-21	Unavailable	Unavailable	3 / 4
2026-09-22	Unavailable	Unavailable	3 / 4
2026-09-23	Unavailable	Unavailable	3 / 4
2026-09-24	Unavailable	Unavailable	3 / 4
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	Unavailable	3 / 4
2026-09-27	Unavailable	Unavailable	3 / 4
2026-09-28	Unavailable	Unavailable	3 / 4
2026-09-29	Unavailable	Unavailable	3 / 4
2026-09-30	Unavailable	Unavailable	3 / 4
2026-10-01	Unavailable	Unavailable	3 / 4
2026-10-02	Unavailable	Unavailable	3 / 4
2026-10-03	Unavailable	Unavailable	3 / 4
2026-10-04	Unavailable	Unavailable	3 / 4
2026-10-05	Unavailable	Unavailable	3 / 4
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	Unavailable	3 / 4
2026-10-10	Unavailable	Unavailable	3 / 4
2026-10-11	Unavailable	Unavailable	3 / 4
2026-10-12	Unavailable	Unavailable	3 / 4
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	Unavailable	3 / 4
2026-10-17	Unavailable	Unavailable	3 / 4
2026-10-18	Unavailable	Unavailable	3 / 4
2026-10-19	Unavailable	Unavailable	3 / 4
2026-10-20	Unavailable	Unavailable	3 / 4
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	6	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway into 2027Direct metric needs a verified mapping
Reduce net loss per shareDirect metric needs a verified mapping
Stabilize or improve revenue trajectoryDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-45.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Coya Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical-stage biotechnology story, not an established earnings compounder. The long-term thesis is in a watch state: trial progress is on track, but recent financial performance is weak and below its industry cohort.

What's priced into Coya Therapeutics Inc

COYA carries a durable premium versus peers, while the expectations gap is substantial. The evidence labels that premium unjustified, so the valuation appears to assume more durability than current results support.

What the fundamentals likely do

Near term, cash declined from $50.7 million in the first quarter of 2026 to $43.2 million in the second, though management says it can fund operations past the ALSTARS data readout and into the second half of 2027. Enrollment in the Phase 2 ALS trial is proceeding as planned, with topline data expected in the first quarter of 2027; management also plans a Phase 2 FTD study in the second half of 2026. Risk is high, and a guidance cut is a stated downside trigger.

What Coya Therapeutics Inc hinges on

The multi-year thesis hinges on trial execution and useful clinical data, alongside keeping the cash runway on track. A guidance cut or further cash pressure would weaken the setup; progress on COYA 302 milestones and continued strength among healthcare bellwethers are favorable signals. Recent litigation filings add uncertainty, but the evidence provides little detail on their substance.